inmagazine.ca Open in urlscan Pro
2607:f1c0:100f:f000::202  Public Scan

Form analysis
3 forms found in the DOM

GET https://inmagazine.ca

<form id="search-form" role="search" method="get" class="default nolabels" action="https://inmagazine.ca">
  <div class="input-wrap">
    <label for="search-input">Search<span class="required">*</span></label>
    <input type="search" placeholder="Search" name="s" id="s" tabindex="0" aria-label="Search" aria-invalid="false" required="">
    <button type="submit"><i class="fas fa-search" aria-hidden="true"></i></button>
  </div>
</form>

POST https://inmagazine.ca/wp-comments-post.php

<form action="https://inmagazine.ca/wp-comments-post.php" method="post" id="commentform" class="comment-form default nolabels">
  <p class="comment-notes"><span id="email-notes">Your email address will not be published.</span> <span class="required-field-message">Required fields are marked <span class="required">*</span></span></p>
  <p class="comment-form-author"><label for="author">Name <span class="required">*</span></label> <input placeholder="Name *" id="author" name="author" type="text" value="" size="30" maxlength="245" autocomplete="name" required="required"></p>
  <p class="comment-form-email"><label for="email">Email <span class="required">*</span></label> <input type="email" placeholder="Email *" id="email" name="email" value="" size="30" maxlength="100" aria-describedby="email-notes" autocomplete="email"
      required="required"></p>
  <div class="input-wrap full"><label for="comment">Comment</label><textarea id="comment" name="comment" aria-required="true" placeholder="Comment *"></textarea></div>
  <p class="form-submit"><button name="submit" type="submit" id="submit" class="submit button">POST COMMENT</button> <input type="hidden" name="comment_post_ID" value="43882" id="comment_post_ID">
    <input type="hidden" name="comment_parent" id="comment_parent" value="0">
  </p>
  <p style="display: none;"><input type="hidden" id="akismet_comment_nonce" name="akismet_comment_nonce" value="87abed1a68"></p>
  <p style="display: none !important;" class="akismet-fields-container" data-prefix="ak_"><label>Δ<textarea name="ak_hp_textarea" cols="45" rows="8" maxlength="100"></textarea></label><input type="hidden" id="ak_js_1" name="ak_js"
      value="1734935093420">
    <script>
      document.getElementById("ak_js_1").setAttribute("value", (new Date()).getTime());
    </script>
  </p>
</form>

POST https://form.flodesk.com/forms/62618575ec93244248594d7b/submit

<form class="ff-62618575ec93244248594d7b__form" action="https://form.flodesk.com/forms/62618575ec93244248594d7b/submit" method="post" data-ff-el="form" novalidate="">
  <div class="ff-62618575ec93244248594d7b__title">
    <div></div>
  </div>
  <div class="ff-62618575ec93244248594d7b__subtitle">
    <div></div>
  </div>
  <div class="ff-62618575ec93244248594d7b__content fd-form-content" data-ff-el="content">
    <div class="ff-62618575ec93244248594d7b__fields" data-ff-el="fields">
      <input type="hidden" name="csrf" value="36ee9925b0c9cc27711ecbed1795332b558e148d158f4ac4af709687340bfaa6efd5d72a8fee60cb3ae8182914b1ad3d5551e04ecdb9a9fe48c28f1831cb81ea">
      <div class="ff-62618575ec93244248594d7b__field fd-form-group" style="display: none;display: none">
        <input id="ff-62618575ec93244248594d7b-TBIdU5iQkQ5Y" class="ff-62618575ec93244248594d7b__control fd-form-control" type="text" maxlength="255" name="TBIdU5iQkQ5Y" placeholder="TBIdU5iQkQ5Y" data-ff-tab="TBIdU5iQkQ5Y::TRxa0YO">
        <label for="ff-62618575ec93244248594d7b-TBIdU5iQkQ5Y" class="ff-62618575ec93244248594d7b__label fd-form-label"><span style="rigth: -100000px;display: nonee">Nam</span><span style="right: -100000px;left: -100000px;display: none">e</span><span
            style="display: nonee">e</span></label>
      </div>
      <div class="ff-62618575ec93244248594d7b__field fd-form-group" style="rigth: -100000px;display: none">
        <input id="ff-62618575ec93244248594d7b-UId5iQkQ5YTB" class="ff-62618575ec93244248594d7b__control fd-form-control" type="text" maxlength="255" name="UId5iQkQ5YTB" placeholder="UId5iQkQ5YTB" data-ff-tab="UId5iQkQ5YTB::0xaYOTR">
        <label for="ff-62618575ec93244248594d7b-UId5iQkQ5YTB" class="ff-62618575ec93244248594d7b__label fd-form-label"><span style="display: none">n</span><span style="display: nonee">N</span><span style="display: nonee">ame</span></label>
      </div>
      <div class="ff-62618575ec93244248594d7b__field fd-form-group" style="dislpay: none;display: none">
        <input id="ff-62618575ec93244248594d7b-BIdU5iQkQ5YT" class="ff-62618575ec93244248594d7b__control fd-form-control" type="text" maxlength="255" name="BIdU5iQkQ5YT" placeholder="BIdU5iQkQ5YT" data-ff-tab="BIdU5iQkQ5YT::Rxa0YOT">
        <label for="ff-62618575ec93244248594d7b-BIdU5iQkQ5YT" class="ff-62618575ec93244248594d7b__label fd-form-label"><span style="display: nonee">Nam</span><span style="display: none">P</span><span style="display: nonee">e</span></label>
      </div>
      <div class="ff-62618575ec93244248594d7b__field fd-form-group" style="display: nonee">
        <input id="ff-62618575ec93244248594d7b-YTBIdU5iQkQ5" class="ff-62618575ec93244248594d7b__control fd-form-control" type="text" maxlength="255" name="YTBIdU5iQkQ5" placeholder="YTBIdU5iQkQ5" data-ff-tab="YTBIdU5iQkQ5::OTRxa0Y">
        <label for="ff-62618575ec93244248594d7b-YTBIdU5iQkQ5" class="ff-62618575ec93244248594d7b__label fd-form-label"><span style="display: nonee;display: nonee">Nam</span><span style="display: none">L</span><span
            style="rigth: -100000px;display: nonee;display: nonee">e</span></label>
      </div>
      <div class="ff-62618575ec93244248594d7b__field fd-form-group" style="display: nonee">
        <input id="ff-62618575ec93244248594d7b-OTRxa0Y" class="ff-62618575ec93244248594d7b__control fd-form-control" type="text" maxlength="255" name="OTRxa0Y" placeholder="OTRxa0Y" data-ff-tab="OTRxa0Y:YTBIdU5iQkQ5:ajdKa0lQcw">
        <label for="ff-62618575ec93244248594d7b-OTRxa0Y" class="ff-62618575ec93244248594d7b__label fd-form-label"><span style="letf: -100000px;display: nonee">Emai</span><span style="rigth: -100000px;display: none">o</span><span
            style="display: nonee">l *</span></label>
      </div>
      <div class="ff-62618575ec93244248594d7b__field fd-form-group" style="display: none;left: -100000px;display: none">
        <input id="ff-62618575ec93244248594d7b-Rxa0YOT" class="ff-62618575ec93244248594d7b__control fd-form-control" type="text" maxlength="255" name="Rxa0YOT" placeholder="Rxa0YOT" data-ff-tab="Rxa0YOT:BIdU5iQkQ5YT:dKa0lQcwaj">
        <label for="ff-62618575ec93244248594d7b-Rxa0YOT" class="ff-62618575ec93244248594d7b__label fd-form-label"><span style="display: nonee">Emai</span><span style="display: none">M</span><span style="display: nonee;display: nonee">l
            *</span></label>
      </div>
      <div class="ff-62618575ec93244248594d7b__field fd-form-group" style="display: none">
        <input id="ff-62618575ec93244248594d7b-0xaYOTR" class="ff-62618575ec93244248594d7b__control fd-form-control" type="text" maxlength="255" name="0xaYOTR" placeholder="0xaYOTR" data-ff-tab="0xaYOTR:UId5iQkQ5YTB:0KalQcwajd">
        <label for="ff-62618575ec93244248594d7b-0xaYOTR" class="ff-62618575ec93244248594d7b__label fd-form-label"><span style="dislpay: none;letf: -100000px;display: nonee">E</span><span style="display: none">z</span><span style="display: nonee">mail
            *</span></label>
      </div>
      <div class="ff-62618575ec93244248594d7b__field fd-form-group" style="display: none">
        <input id="ff-62618575ec93244248594d7b-TRxa0YO" class="ff-62618575ec93244248594d7b__control fd-form-control" type="text" maxlength="255" name="TRxa0YO" placeholder="TRxa0YO" data-ff-tab="TRxa0YO:TBIdU5iQkQ5Y:jdKa0lQcwa">
        <label for="ff-62618575ec93244248594d7b-TRxa0YO" class="ff-62618575ec93244248594d7b__label fd-form-label"><span style="display: nonee">Ema</span><span style="right: -100000px;display: none;display: none">n</span><span
            style="display: nonee">il *</span></label>
      </div>
    </div>
    <div class="ff-62618575ec93244248594d7b__preference">
      <div class="ff-62618575ec93244248594d7b__preference-title">
        <div></div>
      </div>
      <div class="ff-62618575ec93244248594d7b__preference-control">
        <div class="ff-62618575ec93244248594d7b__preference-list">
          <div class="ff-62618575ec93244248594d7b__preference-item" style="">
            <label class="ff-62618575ec93244248594d7b__form-check fd-form-check">
              <input type="checkbox" name="azl1aHlURkU3Lkk" class="fd-form-check__input" value="ajdKa0lQcw" data-ff-tab="ajdKa0lQcw:OTRxa0Y:submit">
              <span class="fd-form-check__checkmark"></span>
              <span class="fd-form-check__label">I AGREE TO BE EMAILED</span>
            </label>
          </div>
          <div class="ff-62618575ec93244248594d7b__preference-item" style="display: none;">
            <label class="ff-62618575ec93244248594d7b__form-check fd-form-check">
              <input type="checkbox" name="azl1aHlURkU3Lkk" class="fd-form-check__input" value="jdKa0lQcwa" data-ff-tab="jdKa0lQcwa:TRxa0YO:submit">
              <span class="fd-form-check__checkmark"></span>
              <span class="fd-form-check__label">I AGREE TO BE EMAILED</span>
            </label>
          </div>
          <div class="ff-62618575ec93244248594d7b__preference-item" style="display: none;">
            <label class="ff-62618575ec93244248594d7b__form-check fd-form-check">
              <input type="checkbox" name="azl1aHlURkU3Lkk" class="fd-form-check__input" value="dKa0lQcwaj" data-ff-tab="dKa0lQcwaj:Rxa0YOT:submit">
              <span class="fd-form-check__checkmark"></span>
              <span class="fd-form-check__label">I AGREE TO BE EMAILED</span>
            </label>
          </div>
          <div class="ff-62618575ec93244248594d7b__preference-item" style="display: none;">
            <label class="ff-62618575ec93244248594d7b__form-check fd-form-check">
              <input type="checkbox" name="azl1aHlURkU3Lkk" class="fd-form-check__input" value="0KalQcwajd" data-ff-tab="0KalQcwajd:0xaYOTR:submit">
              <span class="fd-form-check__checkmark"></span>
              <span class="fd-form-check__label">I AGREE TO BE EMAILED</span>
            </label>
          </div>
        </div>
      </div>
    </div>
    <div class="ff-62618575ec93244248594d7b__footer" data-ff-el="footer">
      <button type="submit" class="ff-62618575ec93244248594d7b__button fd-btn" data-ff-el="submit" data-ff-tab="submit">
        <span>Subscribe</span>
      </button>
    </div>
  </div>
  <div class="ff-62618575ec93244248594d7b__success fd-form-success" data-ff-el="success">
    <div data-paragraph="true">Thank you for subscribing!</div>
  </div>
  <div class="ff-62618575ec93244248594d7b__error fd-form-error" data-ff-el="error"></div>
</form>

Text Content

Skip to Content
Celebrating Canada's 2SLGBTQI+ Communities

 * Current Issue
   * Issue Archives
 * Latest
 * Community Directory
 * Life
 * Entertainment
 * Travel
 * Style
 * About
 * Advertising
 * Contact

Search*
Home / Health & Fitness / Gilead’s Twice-Yearly Shot To Prevent HIV Succeeds In
Phase 3 Trial

(Photo by Artem Podrez/Pexels)


GILEAD’S TWICE-YEARLY SHOT TO PREVENT HIV SUCCEEDS IN PHASE 3 TRIAL

09 July 2024
Health & Fitness Latest Life
IN Magazine
0 Comments
Share


For the very first time, an HIV PrEP drug candidate has shown zero infections in
a late-stage trial…

An experimental twice-a-year injection of a new antiviral drug to prevent HIV,
called lenacapavir, was 100 per cent effective in a late-stage trial, according
to Gilead Sciences Canada.

In its Phase 3 PURPOSE 1 trial, which was conducted in South Africa and Uganda,
none of the 2,134 cisgender women aged 16-25 who received lenacapavir contracted
HIV after using the twice-a-year injections. The exciting results bring Gilead
one step closer to introducing a new form of pre-exposure prophylaxis, or PrEP,
and broadening its HIV prevention offerings.

“With early data showing zero infections and 100 per cent efficacy, twice-yearly
lenacapavir has potential as a new option to prevent HIV transmission,” said
Wendy Arnott, executive director of medical affairs at Gilead. “We remain
focused on our goal of ending the HIV epidemic globally and here in Canada. We
look forward to seeing further results from the PURPOSE clinical program.”

The age group targeted by the trial is the worst affected by HIV in southern
Africa. In 2022, more than three quarters of infections in 15- to 24-year-olds
in the region were in girls and women, according to UNAIDS.

Every week in 2022, 4,000 adolescent girls and young women aged 15–24 years
became infected with HIV globally, and 3,100 of these infections occurred in
sub-Saharan Africa, according to UNAIDS.

The announcement of the trial’s success has been widely hailed as a huge
breakthrough in the HIV sector, where a vaccine has been elusive.

The next steps for the pharmaceutical company will be to replicate these
results. Later this year or early next year, Gilead expects to share data from
an ongoing Phase 3 study of men who have sex with men. That trial, PURPOSE 2, is
assessing twice-yearly lenacapavir for PrEP in men who have sex with men,
transgender people and non-binary people, and is currently underway in
Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States.
If the results from that trial are positive, the pharmaceutical company could
bring lenacapavir for PrEP to market as soon as late 2025.

More than a decade ago, Gilead’s Truvada became the first approved PrEP for
people without HIV who are at high risk of acquiring it. Daily pills dominate
the market, but drug manufacturers are now focusing on developing longer-acting
shots.

Health policymakers and advocates hope to better prevent the spread of HIV with
longer-acting options that could reach people who either can’t or don’t want to
take a daily pill. HIV remains an epidemic in Canada, with six Canadians dying
on average every week of HIV-related illnesses, and 35 more diagnosed with HIV
every single week, according to surveillance data from the Government of Canada.
While the currently available oral HIV prevention options can reduce the risk of
acquiring sexually transmitted HIV by more than 90 per cent when taken as
prescribed, barriers remain, including recurring medication use, stigma,
discrimination, and low awareness of transmission behaviours and prevention.

For more information about Gilead Sciences Canada, visit www.gilead.ca.

POST TAGS: Gilead hiv PrEP



RELATED ARTICLES

December 6, 2023 / Health & Fitness Latest Life


FIVE WAYS TO WARD OFF THE WINTER BLUES

What you can do to boost your mood this winter

November 7, 2023 / Health & Fitness Latest Life


YOUR BREAST SELF

What Spencer, a trans man, and 30 other Canadians want you to know about breast
cancer…especially if you think it’ll never happen to you

October 12, 2023 / Health & Fitness Latest


MGEN: THE STI YOU MIGHT NOT KNOW ABOUT

Raising awareness about Mycoplasma genitalium, the under-recognized sexually
transmitted infection

POST A COMMENT Cancel reply

Your email address will not be published. Required fields are marked *

Name *

Email *

Comment

POST COMMENT



Δ

Load More


LATEST ISSUE

November / December 2024



Inside this issue you will find: Jody Watley opens up on disrupting and
diversifying the dance floor and the fashion world for more than four decades;
Jinkx Monsoon and BenDeLaCreme are making Christmas queer; Multiple Juno
Award-nominated singer- songwriter Shawnee Kish releases her first-ever
Christmas single; Actor/comedian/social media star Pete Zias; 10 things to know
about trans actress Karla Sofía Gascón, who could make Oscar history; The ACAS
offers a voice for PLHIV in the East and Southeast Asian community; Giving voice
to a transgender musical icon; and much more.



Download this issue for free




EDITOR'S PICKS

 * Community Resource Directory
 * Flashback
 * Queer Crime
 * Canada’s Drag Race Recaps
 * RuPaul’s Drag Race All Stars Recaps
 * RuPaul’s Drag Race Recaps
 * IN Community
 * IN Magazine Issue Archives
 * IN's monthly newsletter
 * Community Partners
 * Elevate Media Group


POPULAR POSTS

 * LifeSex
   
   
   BETWEEN THE SHEETS: WHAT DOES A PROSTATE ORGASM FEEL LIKE?

 * LatestLife
   
   
   THE COURT DATE FOR AUSTIN WOLF'S FIRST HEARING IN HIS FEDERAL CRIMINAL CASE
   HAS BEEN DELAYED YET AGAIN

 * LatestLifeSex
   
   
   BOTTOMS UP: A PREPARATION GUIDE FOR ANAL SEX

 * LatestLifeSex
   
   
   A SEX EDUCATOR’S GUIDE TO GIVING GREAT HEAD

 * EntertainmentLatest
   
   
   HERE ARE THE BEST MOVIES OF 2024, ACCORDING TO JOHN WATERS




NEWSLETTER SIGNUP

Subscribe to the IN newsletter. All Canadian. All Queer. Right to your inbox
every month.

Receive links to our fave stories and find out when our new issues come out!
Sent directly to your inbox at the beginning of every month! Just enter your
name and email address. We’ll take care of the rest.

Namee
nName
NamPe
NamLe
Emaiol *
EmaiMl *
Ezmail *
Emanil *
I AGREE TO BE EMAILED
I AGREE TO BE EMAILED
I AGREE TO BE EMAILED
I AGREE TO BE EMAILED
Subscribe
Thank you for subscribing!




© 2024 2SLGBTQI+ Magazine - Inmagazine.ca All Rights Reserved. / Site Map /
Privacy / Current Issue / Latest / Community Directory / Life / Entertainment /
Travel / Style / About / Advertising / Contact

Website design by Mouth Media Inc.